专利检索 ap:("UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE" OR "INSERM ( INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)" OR "UNIVERSITE DE ROUEN-NORMANDIE" OR "CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)" OR "INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA)" OR "ECOLE NORMALE SUPERIEURE DE LYON" OR "UNIVERSITE CLAUDE BERNARD LYON 1") AND inv:"Abderrazzaq BENTAHER" 第 1 页

1.

发明申请
N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS 有权

公开(公告)号：US20230013304A1

公开(公告)日：2023-01-19

申请号：US17780148

申请日：2020-11-30

申请人： UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE , INSERM ( INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE ROUEN-NORMANDIE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) , INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) , ECOLE NORMALE SUPERIEURE DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1

发明人： Stéphane GERARD , Jean-Philippe BOUILLON , Abderrazzaq BENTAHER , Eric HENON , Jacky JACQUOT , Janos SAPI , Frédéric VELARD

IPC分类号： C07D237/14 , A61K31/501 , A61K45/06 , C07D409/06 , C07D401/04

摘要： The invention relates to compounds of Formula I: or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, in particular cystic fibrosis.